tert-butyl N-[N'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: tert-butyl N-[N'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate
• 化学式: C₇H₁₂F₃N₃O₄S
• 分子量: 291.25
• InChiKey: DDWNLZAZYDDEHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] CEPHEM COMPOUNDS<br/>[FR] COMPOSES CEPHEME
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004039814A1

  公开（公告）日：2004-05-13

  The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种具有以下式[I]的化合物：其中R1是较低的烷基、羟基(较低)烷基或卤代(较低)烷基，R2是氢或氨基保护基，或者R1和R2结合在一起形成较低的烷基或较低的烯基；R3是氢或较低的烷基；R4是；R5是羧基或保护羧基；R6是氨基或保护氨基，或其药学上可接受的盐，一种制备上述式[I]化合物的方法，以及包含上述式[I]化合物与药学上可接受的载体混合物的药物组合物。
• [EN] PROCESS FOR THE PREPARATION OF GUANIDINO SUBSTITUTED BI-AND POLYPHENYLS THAT ARE SUITABLE AS SMALL MOLECULE CARRIERS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BI- ET POLYPHÉNYLES GUANIDINO SUBSTITUÉS CONSTITUANT DE BONS VECTEURS DE PETITES MOLÉCULES
  申请人：UCL BUSINESS PLC

  公开号：WO2009027679A1

  公开（公告）日：2009-03-05

  A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Formula (I) which process comprises:(a) coupling a compound of formula (II) to a compound of formula (III) to form a compound of formula (IV).

  生产化合物(I)或其药用盐的方法，该方法包括：(a)将化合物(II)偶联到化合物(III)以形成化合物(IV)的步骤。
• [EN] 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS<br/>[FR] INHIBITEURS PEPTIDOMIMÉTIQUES DE L'INTÉGRINE À BASE DE 1,2,3 TRIAZOLE POUR LE DIAGNOSTIC ET LE TRAITEMENT DE TUMEURS
  申请人：UNIV FIRENZE

  公开号：WO2011098603A1

  公开（公告）日：2011-08-18

  The present invention refers to the field of chemical compounds bearing a 1,2,3-triazole ring of formula (I) and possessing guanidino and carboxylic groups or their isosteres, their preparation by Cu-catalyzed "click-chemistry", and medical - diagnostic use in pathologies where angiogenesis is altered, for example pathologic conditions of tumor origin, tumor metastasis, osteoporosis, and rheumatoid arthritis.

  本发明涉及具有1,2,3-三唑环的化合物领域，其化学式为(I)，并具有胍基和羧基或其同系物，通过Cu催化的“点击化学”制备，用于在血管生成受损的病理情况中的医疗诊断用途，例如肿瘤来源的病理条件、肿瘤转移、骨质疏松症和类风湿性关节炎。
• Non-covalent inhibitors of urokinase and blood vessel formation
  申请人：CORVAS INTERNATIONAL, INC.

  公开号：EP1182207A2

  公开（公告）日：2002-02-27

  Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

  本研究提供了具有作为尿激酶非共价抑制剂的活性和减少或抑制血管形成的活性的新型化合物。这些化合物的 P1 基团具有脒基或胍基或其衍生物。这些化合物在体外可用于监测纤溶酶原激活剂的水平，在体内可用于治疗因抑制或降低尿激酶活性而改善的病症，以及治疗血管形成与病症有关的病症。
• NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR
  申请人：Shin Nippon Biomedical Laboratories, Ltd.

  公开号：EP3018125A1

  公开（公告）日：2016-05-11

  [Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.         R1-R2-R3-R4     (A)

  [问题]本发明解决了提供一种新型化合物的问题。本发明还解决了提供一种 OCT3 检测剂或 OCT3 活性抑制剂的问题，其中包括该新型化合物。 [解决方案] 由式（A）代表的化合物、其药学上可接受的盐或其药学上可接受的溶液。 R1-R2-R3-R4 (A)